Clinical Trial Update: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating rosiglitazone extended-release as monotherapy in mild-to-moderate Alzheimer's disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Rosiglitazone Extended Release Tablets (rosiglitazone)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Alzheimer's Disease | Phase 3 | Status: COMPLETED | Results posted: 2017-05-19